



저작자표시-비영리-변경금지 2.0 대한민국

이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게

- 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.

다음과 같은 조건을 따라야 합니다:



저작자표시. 귀하는 원저작자를 표시하여야 합니다.



비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다.



변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다.

- 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건을 명확하게 나타내어야 합니다.
- 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.

저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다.

이것은 [이용허락규약\(Legal Code\)](#)을 이해하기 쉽게 요약한 것입니다.

[Disclaimer](#)

의학석사 학위논문

**A study on the mechanism underlying  
activated platelets-mediated conversion of  
CD14<sup>+</sup>CD16<sup>-</sup> into CD14<sup>+</sup>CD16<sup>+</sup>  
monocytes with enhanced FcγR-mediated  
phagocytosis and skewed M2 polarization**

활성 혈소판에 의하여 CD14<sup>+</sup>CD16<sup>-</sup> 단핵구가 강화된  
FcγR 매개 식세포 작용 및 M2 대식세포 특성을 가지는  
CD14<sup>+</sup>CD16<sup>+</sup> 단핵구로 전환되는 기전 연구

2022년 8월

서울대학교 대학원

의과학과 의과학 전공

이수정

**A study on the mechanism underlying  
activated platelets-mediated conversion of  
CD14<sup>+</sup>CD16<sup>-</sup> into CD14<sup>+</sup>CD16<sup>+</sup>  
monocytes with enhanced FcγR-mediated  
phagocytosis and skewed M2 polarization**

지도 교수 이 원 우

이 논문을 의학석사 학위논문으로 제출함  
2022년 4월

서울대학교 대학원  
의과학과 의과학 전공  
이 수 정

이수정의 의학석사 학위논문을 인준함  
2022년 7월

위 원 장 \_\_\_\_\_ (인)

부위원장 \_\_\_\_\_ (인)

위 원 \_\_\_\_\_ (인)

**A study on the mechanism underlying  
activated platelets-mediated conversion of  
CD14<sup>+</sup>CD16<sup>-</sup> into CD14<sup>+</sup>CD16<sup>+</sup> monocytes  
with enhanced FcγR-mediated  
phagocytosis and skewed M2 polarization**

**By**

**Su Jeong Lee**

**(Supervised Prof. Won-Woo Lee)**

**A thesis submitted to the Department of medicine in partial  
fulfillment of the requirements for the Degree of Master of  
Science in Medicine at Seoul National University College of  
Medicine**

**July 2022**

**Approved by Thesis Committee:**

**Professor \_\_\_\_\_ Chairman**

**Professor \_\_\_\_\_ Vice chairman**

**Professor \_\_\_\_\_**

## **Abstract**

# **A study on the mechanism underlying activated platelets-mediated conversion of CD14<sup>+</sup>CD16<sup>-</sup> into CD14<sup>+</sup>CD16<sup>+</sup> monocytes with enhanced FcγR-mediated phagocytosis and skewed M2 polarization**

Su Jeong Lee

The Department of Biomedical Sciences

The Graduate School

Seoul National University

Monocytes are important cellular effectors of innate immune defense. Human monocytes are heterogeneous and can be classified into three distinct subsets based on CD14 and CD16 expression. The expansion of intermediate CD14<sup>+</sup>CD16<sup>+</sup> monocytes has been reported in chronic inflammatory diseases including rheumatoid arthritis (RA). However, the mechanism underlying induction of CD16 and its role in monocytes remains poorly understood. Here, I demonstrate that activated platelets are important for induction of CD16 on classical CD14<sup>+</sup>CD16<sup>-</sup> monocytes by soluble factors such as cytokines. Cytokine neutralization and signaling inhibition assays reveal that sequential involvement of platelet-derived TGF-β and monocyte-derived IL-6 contribute to CD16 induction on CD14<sup>+</sup>CD16<sup>-</sup>

monocytes. Activated platelet-induced CD16 on monocytes participates in antibody-dependent cellular phagocytosis (ADCP) and its level is positively correlated with phagocytic activity. CD14<sup>+</sup>CD16<sup>-</sup> monocytes treated with activated platelets preferentially differentiate into M2 macrophages, likely the M2c subset expressing CD163 and MerTK. Lastly, the amount of sCD62P, a marker of activated platelets, is significantly elevated in plasma of RA patients and positively correlates with clinical parameters of RA. The findings suggest an important role of activated platelets in modulating phenotypical and functional features of human monocytes. This knowledge increases understanding of the immunological role of CD14<sup>+</sup>CD16<sup>+</sup> cells in chronic inflammatory diseases.

**Keywords :** Platelet, CD14<sup>+</sup>CD16<sup>+</sup> monocyte, TGF- $\beta$ , IL-6, phagocytosis, M2 macrophages, Rheumatoid arthritis (RA), soluble CD62P, MerTK

**Student Number :** 2018-25031

# CONTENTS

Abstract.....	i
Contents .....	iii
List of Tables and Figures.....	iv
List of Abbreviations .....	vi
Introduction .....	1
Material and methods .....	5
Results .....	13
Discussion.....	47
References .....	58
Abstract in Korean.....	65

## LIST OF TABLES AND FIGURES

Table 1. The characteristics of RA patients .....	7
Table 2. List of primer sequences for real-time PCR .....	10
Figure 1. Freshly purified platelets are resting state and are activated with ADP .....	15
Figure 2. Activated platelets do not effect on cell viability on monocytes .....	16
Figure 3. Activated platelets induce CD16 expression on CD14 <sup>+</sup> CD16 <sup>-</sup> monocytes.....	17
Figure 4. No direct effect of ADP on induction of CD16 expression in CD14 <sup>+</sup> CD16 <sup>-</sup> monocytes.....	18
Figure 5. TGF- $\beta$ , IL-6, and IL-10 induce CD16 expression on CD14 <sup>+</sup> CD16 <sup>-</sup> monocytes.....	19
Figure 6. TGF- $\beta$ and IL-6 are increased in monocytes cultured with activated platelets .....	22
Figure 7. TGF- $\beta$ , not IL-10 and IL-6, is increased in ADP-activated platelet. . .....	23
Figure 8. The production of IL-1 $\beta$ and TNF- $\alpha$ is comparable between monocytes co-cultured with unstimulated platelets and ADP-activated platelets.....	24
Figure 9. Direct contact between monocytes and activated platelets is dispensable for CD16 induction .....	25
Figure 10. TGF- $\beta$ and IL-6 are responsible for activated platelet-mediated induction of CD16 on monocytes.....	27

Figure 11. The phospho-STAT3 and phospho-SMAD3 were increased in monocytes cultured with activated platelets .....	29
Figure 12. Activated platelet-induced CD16 expression is mediated by SMAD3 and STAT3 signaling .....	30
Figure 13. Activated platelet-induced CD16 expression on monocytes is involved in CD16 <sup>-</sup> dependent phagocytosis .....	33
Figure 14. Activated platelet-induced CD16 expression on monocytes is involved in CD16 <sup>-</sup> dependent phagocytosis .....	35
Figure 15. CD14 <sup>+</sup> monocytes treated with activated platelets derived macrophages increase M2-related genes, <i>CD16</i> , <i>CD163</i> and <i>MerTK</i> .....	38
Figure 16. CD14 <sup>+</sup> monocytes treated with activated platelets derived macrophages decrease CD80 and increase CD16 and MerTK.....	39
Figure 17. CD14 <sup>+</sup> monocytes treated with activated platelets and GM-CSF derived macrophages have M2 macrophage phenotype.....	40
Figure 18. CD14 <sup>+</sup> monocytes treated with activated platelets derived macrophages increase the phagocytosis of apoptotic cells.....	42
Figure 19. soluble CD62P, a marker of platelet activation, was increased in RA patients .....	45
Figure 20. Clinical relevance of enhanced soluble CD62P in RA patients .....	46
Figure 21. Marked inhibition of activated platelet-induced CD16 by the TGF-βRI inhibitor, SB431542.....	52

## **LIST OF ABBREVIATIONS**

ADCC : Antibody-dependent cell-mediated cytotoxicity

ADCP : Antibody-dependent cellular phagocytosis

ADP : Adenosine diphosphate

CDC : Complement-dependent cytotoxicity

CRP : C-reactive protein

CXCL- : Chemokine (C-X-C motif) ligand-

DAS28 : Disease activity score-28

ESR : Erythrocyte sedimentation rate

FcγRIII : Fc receptors III

HCs : Healthy controls

HMDM : Human monocyte-derived macrophages

IFN : Interferon

IgG : Immunoglobulin G

IL- : Interleukin

M-CSF : Macrophage colony-stimulating factor

MerTK : MER proto-oncogenes, tyrosine kinase

MPAs : Monocyte-platelet aggregates

MRC1 : Mannose receptor C-type 1

PBMC : Peripheral blood mononuclear cells

PF4 : Platelet factor 4

PRP : Platelet-rich plasma

RA : Rheumatoid arthritis

ROS : Reactive oxygen species

sCD62P : soluble CD62P

SLE : Systemic lupus erythematosus

SMAD3 : Mothers against decapentaplegic homolog 3

STAT3 : Signal transducer and activator of transcription 3

TGF- $\beta$  : Transforming growth factor  $\beta$

TNF : Tumor necrosis factor

# INTRODUCTION

Monocytes are circulating blood leukocytes typically regarded as systemic precursors of macrophages and dendritic cells (DCs)<sup>1-3</sup>. Besides their primary role as precursors, monocytes also act as important innate effectors in the pathogenesis of various inflammatory diseases as well as in the inflammatory response against infectious pathogens through phagocytosis, production of reactive oxygen species (ROS), secretion of proinflammatory soluble factors, and the activation of adaptive immunity<sup>4,5</sup>. In humans, peripheral monocytes are heterogeneous and classified into three functionally distinct subsets depending on the expression of CD14, a coreceptor for LPS, and CD16 (also known as FcγRIII). These include classical CD14<sup>+</sup>CD16<sup>-</sup>, intermediate CD14<sup>+</sup>CD16<sup>+</sup>, and nonclassical CD14<sup>dim</sup>CD16<sup>+</sup> monocytes<sup>6-9</sup>. In vivo deuterium labeling experiments revealed that CD14<sup>+</sup>CD16<sup>-</sup> monocytes have the potential to become CD14<sup>+</sup>CD16<sup>+</sup> monocytes before finally differentiating into CD14<sup>dim</sup>CD16<sup>+</sup> monocytes under steady state and experimental endotoxemic conditions<sup>10</sup>. Moreover, CD16<sup>+</sup> monocytes are expanded in patients with inflammatory disorders including several autoimmune diseases<sup>11-13</sup>, and platelets are a major factor contributing to the induction of CD16 expression on human monocytes<sup>14</sup>. However, the mechanisms underlying the induction of CD16 are not fully understood.

During inflammatory responses, circulating monocytes move into the inflamed region and develop into inflammatory macrophages<sup>6,61</sup>. Depending on the surrounding microenvironmental stimuli and signals, macrophages can be polarized into phenotypically and functionally distinct proinflammatory M1 or anti-inflammatory/pro-resolving M2 macrophages<sup>37,38</sup>. Furthermore, M2 macrophages can be subcategorized as M2a, M2b, M2c, or M2d according to the applied stimuli, the resulting transcriptional alterations, and functions<sup>39</sup>. These macrophages differ in cell surface molecules, the profile of secreted cytokines, and their biological roles. It has been well demonstrated that M2 polarization occurs in response to downstream signals from cytokines such as IL-4, IL-13, IL-6, IL-10, and TGF- $\beta$ <sup>71</sup>. Especially, glucocorticoids, IL-10, and TGF- $\beta$  trigger the polarization of M2c macrophages, which are able to release IL-10, TGF- $\beta$ , CCL16, and CCL18 and play an essential role in the phagocytosis of apoptotic cells<sup>72</sup>. Mer tyrosine kinase (MerTK) is a key apoptotic cell (AC) receptor in macrophages and is one of the markers defining M2c macrophages. Recent studies have identified M2c-like cells among circulating CD14<sup>+</sup>CD16<sup>+</sup> monocytes but not CD14<sup>+</sup>CD16<sup>-</sup> and CD14<sup>dim</sup>CD16<sup>+</sup> monocytes<sup>70</sup>.

Platelets are circulating, tiny, anucleate cells that play a prominent role in hemostasis and thrombosis<sup>15</sup>. However, platelets are also involved in aiding and modulating inflammatory reactions and immune responses. This

occurs through immune ligands and receptors on the platelet surface and through release of an abundance of secretory molecules, including inflammatory mediators and cytokines<sup>16</sup>. Upon activation, platelets change their shape and form aggregates. In addition, P-selectin (CD62P) expressed on activated platelets mediates the formation of monocyte-platelet aggregates (MPAs), which is an essential pathophysiological mechanism that mediates the induction of inflammatory events by activated platelets<sup>17,18</sup>. Several studies have shown increased levels of circulating MPAs in the peripheral blood of patients with atherosclerosis, type I diabetes, and end-stage renal diseases<sup>19-22</sup>. In several autoimmune diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), platelets are considered active players that produce serotonin and IL-1-containing microparticles<sup>23-26</sup>. Further, platelets promote macrophage polarization toward the proinflammatory phenotype in response to LPS stimulation resulting in increased survival of septic mice<sup>27</sup>, whereas platelet-lymphocyte interactions mediate anti-inflammatory events in RA<sup>28</sup>. Together this suggests platelets play a regulatory role in innate as well as adaptive immune responses<sup>15,29</sup>.

In previous study I demonstrated that CD14<sup>+</sup>CD16<sup>+</sup> monocytes are markedly expanded in peripheral blood and synovial fluid of RA patients. Further, CD16 expression on CD14<sup>+</sup> monocytes are induced by TGF- $\beta$  without additive effects of co-treatment with IL-1 $\beta$ , TNF- $\alpha$  or IL-6, which are typical proinflammatory cytokines produced by activated monocytes<sup>11</sup>.

Given the involvement of platelets in the pathophysiology of RA and their role as a major reservoir of TGF- $\beta$ <sup>30</sup>, I sought to investigate the underlying mechanisms of CD16 induction on monocytes and the immunological role of this receptor under co-culture conditions with activated, autologous platelets.

In the present study, I demonstrate that CD16 expression is induced by exposure to the cytokine milieu generated in monocyte and ADP-activated platelet co-cultures. Exogenous cytokine treatment and neutralization assay showed that both platelet-derived TGF- $\beta$  and monocyte-derived IL-6 are sequentially involved in the induction of CD16 expression on purified CD14<sup>+</sup>CD16<sup>-</sup> monocytes. Induced CD16 participates in IgG-mediated phagocytosis, as shown by the correlation between the level of CD16 expression by monocytes co-cultured with activated platelets and the CD16<sup>-</sup>dependent uptake of latex beads coated with FITC-labeled IgG. In addition, monocytes pretreated with activated platelets preferentially differentiate into M2c-like macrophages in the presence of M-CSF. Lastly, the amount of sCD62P, a marker of platelet activation, was found to be significantly elevated in plasma of RA patients compared with that of healthy controls and positively correlated with clinical parameters of RA patients. These findings underscore the important role of activated platelets in modulating phenotypical and functional features of human monocytes. Together these findings increase understanding of the immunological role of CD14<sup>+</sup>CD16<sup>+</sup> monocytes in various inflammatory disorders.

# MATERIAL AND METHODS

## Cell preparation

The study protocols were approved by the institutional review board (IRB) of Seoul National University Hospital and Chungnam National University Hospital. Peripheral blood of RA patients and healthy controls (HCs) was drawn after obtaining written, informed consent. The methods were performed in accordance with the approved guidelines. The patient characteristics of RA patients enrolled in this study are summarized in Table 1. To obtain platelets, platelet-rich plasma (PRP) was prepared from whole blood by centrifugation at 190 *g* for 15 min at room temperature (RT). Subsequently, platelet pellet was prepared from PRP by centrifugation at 2,400 *g* for 5 min and was resuspended with 25 mM HEPES-buffered Tyrode's solution (Sigma-Aldrich, St. Louis, MO). Peripheral blood mononuclear cells (PBMC) were isolated from blood by density gradient centrifugation (Bicoll separating solution; BIOCHROM Inc., Cambridge, UK). To purify CD14<sup>+</sup>CD16<sup>-</sup> monocytes, CD16<sup>+</sup> monocytes were negatively depleted from PBMC with CD16<sup>+</sup> Monocyte Isolation Kit (Miltenyi Biotec Inc., Auburn, CA) and CD14<sup>+</sup> monocytes were positively purified from CD16<sup>+</sup> cell-depleted PBMC using anti-CD14 microbeads (Miltenyi Biotec Inc.). Human neutrophils were isolated from blood by density gradient centrifugation (BIOCHROM Inc.) and lysis of

contaminating erythrocytes by incubation with RBC lysis buffer (BD Bioscience, San Jose, CA). Neutrophils were resuspended in PBS and labeled with 2.5  $\mu$ M CFSE (Thermo Fisher Scientific, Waltham, MA).

**Table 1. The characteristics of RA patients**

Patient Characteristics (Value)	Age (years), means $\pm$ SD	57.84 $\pm$ 8.81
	Sex (female/male), <i>N</i> (%)	24/8 (75.00/25.00)
	Disease duration, months	5.48 $\pm$ 5.12
	Rheumatoid factor – no. of positive (%)	28/32 (87.50)
	Rheumatoid factor titer (IU/ml), means $\pm$ SD	122.90 $\pm$ 87.70
	Anti-citrullinated protein antibody, no. of positive (%)	25/32 (78.13)
	Anti-citrullinated protein antibody titer (IU/ml), means $\pm$ SD	357.88 $\pm$ 161.59
	ESR (mm/h), means $\pm$ SD	26.81 $\pm$ 23.98
	CRP (mg/dl), means $\pm$ SD	2.00 $\pm$ 6.17
	DAS28 ESR, means $\pm$ SD	3.36 $\pm$ 1.62
	DAS28 CRP, means $\pm$ SD	2.42 $\pm$ 1.29
Medications [No. (%)]	Steroid (Prednisolone)	25/32 (78.13)
	Methotrexate	27/32 (84.38)
	Sulfasalazine	10/32 (31.25)
	Hydroxychloroquine	15/32 (46.88)
	Leflunomide	1/32 (3.13)
	TNF inhibitor (Infliximab)	1/32 (3.13)

ESR: erythrocyte sedimentation rate

CRP: C-reactive protein

DAS28: Disease Activity Score-28

DAS28-ESR: DAS28 for RA based on ESR

DAS28-CRP: DAS28 for RA based on CRP

### **Co-culture of monocytes and activated platelets**

Purified CD14<sup>+</sup>CD16<sup>-</sup> monocytes were cultured in RPMI 1640 medium supplemented with 10% charcoal stripped fetal bovine serum, 1% penicillin/streptomycin, and 1% L-glutamine. Platelets were activated with ADP (10 µg/ml) for 5 min at RT. CD14<sup>+</sup>CD16<sup>-</sup> monocytes were co-cultured with activated platelets at 1:100 ratio for 18 hr at 37 °C in polystyrene tubes. In some experiments, CD14<sup>+</sup>CD16<sup>-</sup> monocytes and activated platelets were placed in lower- and upper-chamber of Transwell cell culture plate (0.4 µm pore size) (Corning-Costar, Lowell, MA), respectively and cultured for 18 hr at 37 °C. To prepare human monocyte-derived macrophage (HMDM), purified monocytes were pretreated for 18 h with or without ADP-activated platelets and were differentiated into macrophages for 6 days in the presence of recombinant human M-CSF (50 ng/ml; PeproTech, Rocky Hill, NJ) without washing platelets.

### **Cytokine neutralization assay and signaling inhibition assay**

Purified CD14<sup>+</sup>CD16<sup>-</sup> monocytes were pre-incubate for 30 min at 37 °C with anti-IL-6, anti-TGF-β 1,2,3, or anti-IL-10 neutralizing Ab (all from R&D systems, Minneapolis, MN) to examine the effect of above cytokines on CD16 induction by activated platelets. In some experiments, CD14<sup>+</sup>CD16<sup>-</sup> monocytes were pre-incubate for 30 min at 37 °C with 5,15-DPP (STAT3 inhibitor VIII), SIS3 (SMAD3 inhibitor), or SB431542 (TGF-

$\beta$ RI inhibitor) (all from MERCK, Burlington, MA) to examine the effect of TGF- $\beta$  and IL-6-mediated signal transduction on CD16 induction by activated platelets.

### **Flow cytometric analysis**

Cultured monocytes and HMDM were stained for 30 min at 4 °C with following fluorochrome-conjugated Abs: PE-Cy5-anti-HLRHLA-DR, FITC- or APC-Cy7-anti-CD14, PE-anti-CD16, APC-anti-CD62P (all from BD Bioscience), and APC-anti-CD80 (BioLegend, San Jose, CA). The stained cells were acquired using a BD LSR Fortessa (BD Bioscience) and analyzed using Flowjo software (Tree Star, Ashland, OR).

### **Quantitative RT-PCR**

Total RNA was extracted from freshly isolated or cultured cells using TRIzol reagents (Life technologies, Grand Island, NY), and cDNA was synthesized by GoScript reverse transcription system (Promega, Madison, WI). Real-time quantitative RT-PCR was performed in triplicates on a 7500 PCR system (Applied Biosystems, Grand Island, NY) using following primers (Table 2.) The levels of gene expression were normalized to the expression of  $\beta$ -actin. The comparative CT method ( $\Delta\Delta$ CT) was used for the quantification of gene expression.

**Table 2. List of primer sequences for real-time PCR**

<i>Gene</i>	<b>Primer sequence</b>
<i>CD16</i>	Forward 5'-GCTCCGGATATCTTTGGTGA-3'
	Reverse 5'- TTCCAGCTGTGACACCTCAG -3'
<i>TGF-β</i>	Forward 5' - AAGTGGACATCAACGGGTTC -3'
	Reverse 5' -GTCCTTGCGGAAGTCAATGT-3'
<i>IL-6</i>	Forward 5' -AGGAGACTTGCCTGGTGAAA-3'
	Reverse 5' -CAGGGGTGGTTATTGCATCT-3'
<i>IL-10</i>	Forward 5' -TGCCTTCAGCAGAGTGAAGA-3'
	Reverse 5' -GGTCTTGGTTCTCAGCTTGG-3'
<i>CD80</i>	Forward 5' -GGGAAAGTGTACGCCCTGTA-3'
	Reverse 5' -GCTACTTCTGTGCCACCAT-3'
<i>CXCL10</i>	Forward 5' -CAGCAGAGGAACCTCCAGTC-3'
	Reverse 5' -CAAATTGGCTTGCAGGAAT-3'
<i>TNF-α</i>	Forward 5' -AGCCCATGTTGTAGCAAACC-3'
	Reverse 5' -TGAGGTACAGGCCCTCTGAT-3'
<i>MRC1</i>	Forward 5' -TGACACACTTTTGGGGATCA-3'
	Reverse 5' -AAACTTGAACGGGAATGCAC-3'
<i>Dectin-1</i>	Forward 5' -GGGCTCTCAAGAACAATGGA-3'
	Reverse 5' -CCAAGCATAGGATTCCCAA-3'
<i>CD163</i>	Forward 5' -TTTGCTCAAAGGGAGCAGAT-3'
	Reverse 5' -GTTGGACATCCAGTTGCTT-3'
<i>MerTK</i>	Forward 5' -GGGTGAAGGAGAGTTTGGGTC-3'
	Reverse 5' -ACGCTGCCTCACTGAGAAAC-3'
<i>β-actin</i>	Forward 5' -GGACTTCGAGCAAGAGATGG-3'
	Reverse 5' -AGCACTGTGTTGGCGTACAG-3'

### **Enzyme-Linked Immunosorbent Assay (ELISA)**

The amount of TGF- $\beta$ , IL-6, IL-10, IL-1 $\beta$ , TNF- $\alpha$  in culture supernatant and soluble CD62P in plasma of RA patients and HCs was quantified by ELISA kits (all from Thermo Fisher Scientific). The measurement of OD (Optical density) was performed using the infinite 200 pro multimode microplate reader (Tecan Group Ltd., Seestrasse, Switzerland).

### **Immunoblot analysis**

Total proteins were prepared by RIPA buffer (150 mM NaCl, 10 mM Na<sub>2</sub>HPO<sub>4</sub>, pH 7.2, 1% Nonidet P-40, and 0.5% deoxycholate) containing PMSF (phenylmethylsulfonyl fluoride) (Millipore Sigma, Burlington, MA), EDTA, and protease and phosphatase inhibitor cocktail (Thermo Fisher scientific). Cell lysates were separated on an 8-10% SDS-PAGE gel and blotted onto a PVDF membrane (Bio-Rad, Hercules, CA). The membrane was incubated overnight at 4 °C with rabbit anti-human pSTAT3, anti-STAT3, anti-pSMAD3 or anti-SMAD3 polyclonal Ab (all from Cell Signaling Technology, Danvers, MA), followed by incubation with the HRP-conjugated secondary Abs for 1 hr. The membranes were developed by SuperSignal West Femto Maximum Sensitivity substrate kit (Thermo Fisher Scientific, Waltham, MA).

### **Phagocytosis assay**

CD16<sup>-</sup>dependent phagocytic activity of monocytes co-cultured with

platelets were assessed by flow cytometry using Phagocytosis Assay Kit (Cayman Chemical Company, Ann Arbor, MI). Cultured monocytes were pre-incubated at 37 °C for 30 min with anti-CD64 and anti-CD32 neutralizing Abs (all from BioLegend) in the presence or absence of anti-CD16 neutralizing Ab (BD Bioscience). After washing, Latex beads coated with FITC labeled rabbit IgG were added at 1:400 ratio into the cultured monocytes, followed by incubation at 37 °C for 15 min. For induction of phagocytosis of apoptotic cells, apoptotic neutrophils were added for 60 min to macrophages at a 5:1 ratio. The phagocytic activity was evaluated using a BD LSR Fortessa (BD Bioscience).

### **Statistics**


A paired t-test, unpaired t-test, or Pearson correlation analysis was done to analyze data using Prism 7 software (GraphPad Software Inc., La Jolla, CA) as indicated in the figure legends. P-Values of less than 0.05 were considered statistically significant.

# RESULT



## Induction of CD16 on CD14<sup>+</sup>CD16<sup>-</sup> monocytes by activated platelets

The expansion of CD14<sup>+</sup>CD16<sup>+</sup> monocytes has been reported in a variety of inflammatory disorders including rheumatoid arthritis (RA) and inflammatory bowel disease (IBD)<sup>11,12,31</sup>, implying an important role of these cells in disease pathogenesis. Previous study demonstrated that TGF- $\beta$  predominantly induces CD16 expression on conventional CD14<sup>+</sup> monocytes isolated from healthy controls<sup>11</sup>. Considering that platelets are a major reservoir of TGF- $\beta$ , I first tested whether platelets induce CD16 expression on human monocytes. Highly purified CD14<sup>+</sup>CD16<sup>-</sup> monocytes were co-cultured with autologous platelets pretreated with or without adenosine diphosphate (ADP) to activate platelets. FACS analysis using CD62P, a marker of platelet activation, showed that around 10% of platelets were spontaneously activated before adding ADP, probably by physical stress during isolation. However, ADP treatment markedly induced the activation of platelets (Fig. 1). And viability of monocytes was not influenced by activated platelets (Fig. 2). I found that platelets significantly increased the expression of CD16 on CD14<sup>+</sup> monocytes as previously depicted<sup>14</sup>. This induction was intensified by ADP-treatment of platelets (Fig. 3A) in a transcription-dependent manner (Fig. 3B), with markedly elevated *CD16* mRNA expression 18 hr after co-culture. Monocytes treated with ADP alone


did not induce CD16 expression on CD14<sup>+</sup>CD16<sup>-</sup> monocytes (Fig. 4) although it has been known that P2Y12, a receptor for ADP, is expressed on THP-1 human monocyte cells<sup>32</sup>. Activated platelets give rise to an increase of the CD14<sup>+</sup>CD16<sup>+</sup> subset, but had no effect on the appearance of nonclassical CD14<sup>dim</sup>CD16<sup>+</sup> monocytes (Fig. 3A). Although stimulated platelets are a main source of TGF- $\beta$ , the adherence of platelets to monocytes is also known to influence the production of cytokines such as IL-10 and TNF- $\alpha$ <sup>33</sup>. Therefore, I extended analysis to examine which cytokines, in addition to TGF- $\beta$ , induce CD16 expression and compared these findings with the platelet-treatment group. In agreement with previous studies, CD14<sup>+</sup> monocytes treated with exogenous TGF- $\beta$  and IL-10 exhibited significantly enhanced CD16 expression (Fig. 4)<sup>11,14,33,34</sup>. However, the major pro-inflammatory cytokines produced by activated monocytes, IL-1 $\beta$  and TNF- $\alpha$ , exhibited no effect on CD16 induction. Of note, in contrast to other monocyte-derived pro-inflammatory cytokines, such as IL-1 $\beta$  and TNF- $\alpha$ , IL-6 was found to induce CD16 to a degree similar to that induced by TGF- $\beta$  or platelet treatment (Fig. 5). These findings demonstrate that cytokines derived from monocyte-platelet co-cultures are responsible for induction of CD16 on conventional CD14<sup>+</sup> human monocytes.




**Figure 1. Freshly purified platelets are resting state and are activated with ADP.** Isolated platelets were treated for 5 min with or without ADP. Platelets were immediately fixed with 4% formalin and stained with anti-CD62P Ab. The expression of CD62P was analyzed using flow cytometry. Bars plots show the mean  $\pm$  S.E.M. \* =  $p < 0.05$  by two-tailed paired t-test.





**Figure 2. Activated platelets do not effect on cell viability in monocytes.** Purified monocytes were stimulated for 18 h with or without ADP-activated platelets. Cell viability was evaluated using 7-AAD staining.



**Figure 3. Activated platelets induce CD16 expression on CD14<sup>+</sup>CD16<sup>-</sup> monocytes.** (A) Representative contour plots of CD16 expression on monocytes co-cultured with or without activated platelets (right). Highly purified CD14<sup>+</sup>CD16<sup>-</sup> monocytes were co-cultured for 18 hr with resting platelets or ADP-activated platelets. Frequencies (%) of CD14<sup>+</sup>CD16<sup>+</sup> monocytes were analyzed using flow cytometry (left) ( $n = 7$ ). (B) Quantitative RT-PCR analysis of *CD16* in monocytes co-cultured with activated platelets for the indicated times. mRNA expression of *CD16* was normalized to that in monocytes incubated without platelets at the same time points ( $n = 5$  or  $6$ ). Bars show the mean  $\pm$  S.E.M. \* =  $p < 0.05$ , \*\* =  $p < 0.01$ , and \*\*\* =  $p < 0.001$  by two-tailed paired t-test.



**Figure 4. No direct effect of ADP on induction of CD16 expression in CD14<sup>+</sup>CD16<sup>-</sup> monocytes.** Purified monocytes were stimulated for 18 h with ADP alone or ADP-activated platelets. Induction of CD16 expression was analyzed by flow cytometry. Bars plots show the mean  $\pm$  S.E.M. \* =  $p < 0.05$  by two-tailed paired t-test.




**Figure 5. TGF- $\beta$ , IL-6 and IL-10 induce CD16 expression on CD14<sup>+</sup>CD16<sup>-</sup> monocytes.** Representative contour plot of CD16 expression on monocytes co-cultured with activated platelets for 18 hr or treated with the indicated cytokines for 18 hr (upper panel). Frequencies (%) of CD14<sup>+</sup>CD16<sup>+</sup> monocytes under the indicated conditions were analyzed using flow cytometry (lower panel) ( $n = 4$ ). Bars show the mean  $\pm$  S.E.M. \* =  $p < 0.05$ , \*\* =  $p < 0.01$ , and \*\*\* =  $p < 0.001$  by two-tailed paired t-test.

## **TGF- $\beta$ and IL-6 are involved in activated platelet-mediated induction of CD16 on monocytes.**


I next investigate whether the induction of CD16 expression on monocytes by activated platelets is directly attributable to endogenously secreted TGF- $\beta$ , IL-10, or IL-6 in the co-culture. The expression of *IL-10* and *IL-6* mRNA was significantly increased in a time-dependent manner during the co-culture, whereas the *TGF- $\beta$*  mRNA level was not changed until 18 hr after co-culture (Fig. 6A). *TGF- $\beta$*  mRNA level and protein levels were markedly increased in the platelets alone in response to stimulation with ADP, but *IL-10* nor *IL-6* mRNA were barely detected (Fig. 7). ELISA revealed that TGF- $\beta$  was mainly secreted by activated platelets alone and was minimally produced by monocytes cultured with activated platelets thus, a high level of TGF- $\beta$  was maintained over time (Fig. 6B and 7B). This finding was confirmed using a transwell system in which direct contact between monocytes and activated platelets mediated by CD62P was found to be dispensable for CD16 induction at 18 hr after co-culture (Fig. 9). In stark contrast to TGF- $\beta$ , platelets have no ability to produce IL-10 or IL-6 regardless of their activation state. Consistent with its mRNA expression, the amount of IL-6 in the co-culture supernatant increased greatly over time compared with the culture of monocytes alone (Fig. 6B). In contrast, IL-10 was detected in the supernatant a later time-point, although at a relatively low level (Fig 6B). The production of IL-1 $\beta$  and TNF- $\alpha$  was comparable

between co-culture of monocytes and platelets and the culture of monocytes alone (Fig. 8). This suggests that TGF- $\beta$  and IL-6, not IL-10, are the main contributors to the induction of CD16 expression on CD14<sup>+</sup> monocytes co-cultured with activated platelets. To confirm this finding, purified CD14<sup>+</sup> monocytes were cultured with ADP-activated platelets in the presence of neutralizing antibodies for cytokines related to induction of CD16. As expected, neutralization of TGF- $\beta$  and IL-6 significantly diminished the induction of CD16 expression, whereas no inhibitory effect on CD16 expression by IL-10 was observed (Fig. 10). These data suggest that endogenously secreted TGF- $\beta$  and IL-6 are predominantly involved in activated platelet-mediated induction of CD16 on monocytes.




**Figure 6. TGF- $\beta$  and IL-6 are increased in monocytes cultured with activated platelets.** (A) Quantitative RT-PCR analysis of *TGF- $\beta$* , *IL-10*, and *IL-6* in monocytes co-cultured with activated platelets at the indicated time points. mRNA expression of each gene was normalized to that in monocytes incubated without platelets at the same time points ( $n = 5$  or  $6$ ). (B) The amount of TGF- $\beta$ , IL-10, and IL-6 in supernatants of monocytes co-cultured with or without ADP-activated platelets ( $n = 6$  or  $7$ ) or unstimulated platelets ( $n = 3$ ) were quantified (ELISA). Bars show the mean  $\pm$  S.E.M. \* =  $p < 0.05$  and \*\* =  $p < 0.01$  by two-tailed paired  $t$ -test.


## Platelet alone



**Figure 7. TGF- $\beta$ , not IL-10 and IL-6, is increased in ADP-activated platelet.** (A) Quantitative RT-PCR analysis of *TGF- $\beta$* , *IL-10*, and *IL-6* in unstimulated platelets and ADP-activated platelets. mRNA expression of each gene was normalized to that in unstimulated platelets ( $n = 3$ ). (B) The amount of TGF- $\beta$ , IL-10, and IL-6 in supernatants of unstimulated platelets and ADP-activated platelets ( $n = 3$ ) were quantified using ELISA. Bars show the mean  $\pm$  S.E.M. \* =  $p < 0.05$  and \*\* =  $p < 0.01$  by two-tailed paired  $t$ -test.




**Figure 8.** The production of IL-1 $\beta$  and TNF- $\alpha$  is comparable between monocytes co-cultured with unstimulated platelets and ADP-activated platelets. Purified monocytes were stimulated for 18 h with ADP alone or ADP-activated platelets. The amount of IL-1 $\beta$  and TNF- $\alpha$  in supernatants of monocytes were quantified using ELISA ( $n = 3$ ) were quantified (ELISA). Bars show the mean  $\pm$  S.E.M.



**Figure 9. Direct contact between monocytes and activated platelets is dispensable for CD16 induction.** For transwell experiments, ADP-activated platelets were added into upper chamber and purified CD14<sup>+</sup>CD16<sup>-</sup> monocytes were cultured in the lower chamber for 18 h. (A)


Transwell culture system. (B) Representative contour plot of FSC/SSC of monocytes and CD14/CD16 expression on monocytes in the transwell culture system. (C) Representative histogram plots of CD62P expression on monocytes under the indicated conditions (left panel). MFI of CD62P in monocytes under the indicated conditions were analyzed using flow cytometry (right panel) ( $n = 3$ ). (D) Frequencies (%) of CD14<sup>+</sup>CD16<sup>+</sup> monocytes under the indicated conditions were analyzed using flow cytometry (lower panel) ( $n = 3$ ). Bars plots show the mean  $\pm$  S.E.M. \* =  $p < 0.05$  and \*\* =  $p < 0.01$  by two-tailed paired t-test.




**Figure 10. TGF- $\beta$  and IL-6 are responsible for activated platelet-mediated induction of CD16 on monocytes. (A-B)** Representative contour plot of CD16 expression on monocytes co-cultured with activated platelets in the presence of anti-TGF- $\beta$  (10  $\mu$ g/ml), anti-IL-10 (10  $\mu$ g/ml), or anti-IL-6 (10  $\mu$ g/ml) neutralizing antibodies (left panels of C and D). Purified CD14<sup>+</sup>CD16<sup>-</sup> monocytes were incubated with each neutralizing antibody for 30 min, followed by addition of ADP-activated platelets into the culture. Frequencies (%) of CD14<sup>+</sup>CD16<sup>+</sup> monocytes under the indicated conditions were analyzed using flow cytometry (right panels of C and D) ( $n = 4$  or  $5$ ). Bars show the mean  $\pm$  S.E.M. \* =  $p < 0.05$  and \*\* =  $p < 0.01$  by two-tailed paired  $t$ -test.

## **Activated platelet-induced CD16 expression is mediated by SMAD3 and STAT3.**

To further investigate the molecular mechanisms underlying activated platelet-mediated induction of CD16 by monocytes, I sought to investigate whether SMAD3 and STAT3, which are directly phosphorylated by receptor binding of TGF  $\beta$  and IL-6, respectively, were involved in CD16 induction. Due to the technical difficulty of separating monocytes and platelets during the co-culture, the phosphorylation levels of STAT3 and SMAD3 were analyzed in the co-culture samples and were compared with monocytes or platelet-alone culture groups. STAT3 phosphorylation increased in the co-culture supernatant starting at 3 hr, at which time IL-6 was also increased (Fig. 6B) (Fig. 11). SMAD3 was immediately phosphorylated in platelets upon stimulation with ADP, likely in an autocrine manner. When co-cultured with monocytes, activated platelets enhanced the level of SMAD3 phosphorylation over time (Fig. 11). These findings were corroborated by a signal transduction inhibitor assay. SIS3, a SMAD3 inhibitor, and 5,15-DPP, a STAT3 inhibitor, significantly suppressed activated platelet-mediated induction of CD16 by monocytes (Fig. 12). These data illustrate that activated platelets induce TGF- $\beta$  and IL-6 via the SMAD3 and STAT3 pathways, respectively, which are responsible for the induction of CD16 on monocytes.



**Figure 11. The phospho-STAT3 and phospho-SMAD3 were increased in monocytes cultured with activated platelets.** Immunoblot analysis of phosphorylated and total protein expression of STAT3 and SMAD3 in cell lysates from activated platelets alone, monocytes co-cultured with ADP-activated platelets, and monocytes alone at the indicated time points ( $n = 3$ ).






**Figure 12. Activated platelet-induced CD16 expression is mediated by SMAD3 and STAT3 signaling.** Representative contour plot of CD16 expression on monocytes co-cultured for 18 hr with activated platelets in the presence of SIS3 (SMAD3 inhibitor) or 5,15-DPP (STAT3 inhibitor) (left panel). Frequencies (%) of CD14<sup>+</sup>CD16<sup>+</sup> monocytes treated with SIS3 or 5,15-DPP were analyzed using flow cytometry (right panel) ( $n = 4$ ). 0.1% DMSO was used as a vehicle. Bars show the mean  $\pm$  S.E.M. \* =  $p < 0.05$  and \*\* =  $p < 0.01$  by two-tailed paired  $t$ -test.

## **Activated platelet-induced CD16 expression is involved in CD16<sup>-</sup>-dependent phagocytosis in monocytes**


CD16 is an Fc gamma receptor (Fc $\gamma$ R) that binds IgG molecules through their Fc portion. Fc $\gamma$ Rs recognize IgG-coated targets, such as opsonized pathogens or immune complexes (ICs), and provoke antibody-mediated effector functions in innate immune cells. These include antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC)<sup>35,36</sup>. To assess the phagocytic activity of CD16<sup>-</sup>-expressing monocytes, I utilized a flow cytometry-based phagocytosis assay with latex beads coated with FITC-labeled rabbit IgG. To rule out CD64 and CD32-mediated phagocytosis, monocytes were pretreated with anti-CD64/32 neutralizing antibodies and their phagocytic activity was quantified following culture with platelets or ADP-treated platelets (Fig. 13A and Fig. 14) with or without anti-CD16 neutralizing antibody (Fig. 13). Monocytes co-cultured with ADP-activated platelets showed significantly higher phagocytic activity than those incubated with resting platelets. Furthermore, blockade of CD16 with a neutralizing Ab revealed that CD16 partially contributes to the enhanced phagocytic activity of monocytes co-cultured with activated platelets. As seen in Figure 13C, the frequency of the CD14<sup>+</sup>CD16<sup>+</sup> subset 18 hr after co-culture significantly correlated with phagocytic activity (Fig. 13C,  $p < 0.05$ ). These data demonstrate that activated platelet-mediated

induction of CD16 contributes to CD16<sup>-</sup>dependent phagocytosis by monocytes.

**A****B****C**

**Figure 13. Activated platelet-induced CD16 expression on monocytes is involved in CD16<sup>-</sup> dependent phagocytosis.** Purified CD14<sup>+</sup>CD16<sup>-</sup> monocytes were co-cultured with resting platelets or APD-activated platelets for 18 hr. Monocytes were incubated for 15 min with latex beads coated with FITC-labeled rabbit IgG. The phagocytic activity of monocytes was analyzed using flow Ab cytometry. (A) Representative histogram plots of latex bead-based phagocytic activity of monocytes. To evaluate CD16<sup>-</sup> dependent phagocytic activity, CD64 and CD32, both Fc $\gamma$  receptors, were blocked for

30 min by anti-CD64 and anti-CD32 neutralizing antibodies (10 µg/ml of each antibody) and their phagocytic activity was quantified in monocytes co-cultured with resting platelets or ADP-activated platelets and with or without anti-CD16 neutralizing antibody (10 µg/ml). **(B)** Frequency (%) of monocyte phagocytosis of latex beads coated with FITC-labeled rabbit IgG under the indicated conditions. ( $n = 6$ ) **(C)** Correlation between CD16<sup>-</sup>dependent phagocytic activity and the frequency of CD14<sup>+</sup>CD16<sup>+</sup> monocytes after 18 hr-co-culture with ADP-activated platelets ( $n = 7$ ). *P* value was obtained using the Pearson correlation analysis. Bars show the mean ± S.E.M. \* =  $p < 0.05$ , \*\* =  $p < 0.01$  by two-tailed paired *t*-test.




**Figure 14. Activated platelets are important for increased CD16<sup>-</sup> dependent phagocytosis in monocytes.** Purified CD14<sup>+</sup>CD16<sup>-</sup> monocytes were stimulated for 18 h with resting platelets or ADP-activated platelets. After that, monocytes were blocked for 30 min by anti-CD64 and anti-CD32 neutralizing antibodies, followed by incubation of 15 min with latex beads coated with FITC-labeled rabbit IgG. The phagocytic activity of monocytes was analyzed using flow cytometry. Frequency (%) of monocyte phagocytosis of latex beads coated with FITC-labeled rabbit IgG under the indicated conditions. ( $n = 6$ ). Bars plots show the mean  $\pm$  S.E.M. \*\*\* =  $p < 0.005$  by two-tailed paired t-test.

**CD14<sup>+</sup> monocytes treated with activated platelets preferentially differentiate into M2 macrophages.**


Depending on the microenvironmental stimuli and signals, circulating monocytes can differentiate into macrophages with functional heterogeneity<sup>37-39</sup>. To examine whether the cytokine milieu generated by monocyte-platelet co-culture influences macrophage differentiation, highly purified CD14<sup>+</sup>CD16<sup>-</sup> monocytes were pre-treated with ADP-stimulated platelets for 18 hr followed by stimulation with M-CSF for 6 days to allow differentiation into macrophages. On day 6, the expression of typical M1 and M2-related genes was analyzed by quantitative PCR in human monocyte-derived macrophages (HMDMs) in the presence of ADP-activated platelets (Fig. 15). The expression of M1-related genes, such as *CXCL10*, *CD80*, and *TNF- $\alpha$* , was significantly lower in HMDMs pretreated with activated platelets than in untreated HMDMs. However, the expression of some M2-related genes, such as *CD16* and *CD163*, was increased in HMDMs pretreated with activated platelets. Of note, *MerTK*, a marker of M2c macrophages, was significantly upregulated in HMDMs pretreated with activated platelets. This finding was confirmed through flow cytometric analysis (Fig. 16). It has been well known that HMDM differentiated with M-CSF has characteristics of M2 macrophages, whereas HMDM differentiated with GM-CSF has characteristics of M1 macrophages<sup>78</sup>. I wanted to determine whether the macrophage phenotype

was different in the presence of activated platelets under exogenous GM-CSF stimulation compared to that of M-CSF. Highly purified CD14<sup>+</sup>CD16<sup>-</sup> monocytes were differentiated into macrophages by treatment with GM-CSF or M-CSF. Differentiated macrophages had a decreased mRNA level of, *CD80*, and M1-related gene, and increased mRNA levels of *CD16*, *CD163*, and *MerTK*, M2-related genes, in presence of ADP-activated platelets. The protein expression of CD80 and CD163 were confirmed by flow cytometric analysis (Fig 17). Finally, the ability to phagocytose apoptotic cells was tested to confirm the biological role of M2c macrophages. To this end, CFSE-labeled neutrophils were cocultured with HMDMs pretreated with activated platelets. As seen in figure 18, the frequency of CFSE-positive macrophages, which phagocytosed apoptotic neutrophils, significantly increased in the HMDMs in the presence of ADP-activated platelets, indicating that their phagocytic activity was enhanced (Fig. 18C). These data suggest that the cytokine milieu generated by monocyte-activated platelet co-cultures potentiates a polarization to M2 macrophages, and probably M2c macrophages.




**Figure 15. CD14<sup>+</sup> monocytes treated with activated platelets derived macrophages increase M2-related genes, *CD16*, *CD163* and *MerTK*.**

Purified CD14<sup>+</sup> CD16<sup>-</sup> monocytes were pre-co-cultured with ADP-activated platelets for 18 hr followed by stimulation with M-CSF (50 ng/ml) for 6 days to induce differentiation into macrophages. Quantitative RT-PCR analysis of typical M1- (upper panel) and M2-related genes (lower panel) in human monocyte-derived macrophages (HMDMs) ( $n = 5 \sim 8$ ). Bars show the mean  $\pm$  S.E.M. \* =  $p < 0.05$  and \*\* =  $p < 0.01$  by two-tailed paired  $t$ -test.




**Figure 16. CD14<sup>+</sup> monocytes treated with activated platelets derived macrophages decrease CD80 and increase CD16 and MerTK.** Purified CD14<sup>+</sup> CD16<sup>-</sup> monocytes were pre-co-cultured with ADP-activated platelets for 18 hr followed by stimulation with M-CSF (50 ng/ml) for 6 days to induce differentiation into macrophages. Representative histogram plots of CD80, CD16 and MerTK expression in HMDMs differentiated under the indicated conditions (upper panel). Mean fluorescent intensities (MFIs) of CD80, CD16 and MerTK expression on HMDMs pre-cultured with ADP-activated platelets compared with their expression on HMDMs cultured without platelets (lower panel) ( $n = 6$ ). Bars show the mean  $\pm$  S.E.M. \* =  $p < 0.05$  and \*\* =  $p < 0.01$  by two-tailed paired  $t$ -test.



**Figure 17. CD14<sup>+</sup> monocytes treated with activated platelets and GM-CSF derived macrophages have M2 macrophage phenotype.** Purified CD14<sup>+</sup> CD16<sup>-</sup> monocytes were pre-co-cultured with ADP-activated platelets for 18 hr, followed by stimulation with GM-CSF (50 ng/ml) for 6 days to induce differentiation into macrophages. **(A)** Quantitative RT-PCR analysis in HMDMs ( $n = 3$ ). **(B)** Representative histogram plots of CD80 and CD163 expression in HMDMs differentiated under the indicated conditions. MFIs of CD80 and CD163 expression on HMDMs pre-cultured with ADP-

activated platelets compared with their expression on HMDMs cultured without platelets (right panel) ( $n = 3$ ). Bars show the mean  $\pm$  S.E.M. \* =  $p < 0.05$  by two-tailed paired  $t$ -test.




**Figure 18. CD14<sup>+</sup> monocytes treated with activated platelets derived macrophages increase the phagocytosis of apoptotic cells.** Purified monocytes were pre-stimulated with or without ADP-activated platelets for 18 h, followed by macrophage differentiation under M-CSF (No Plt and Plt + ADP group) ( $n = 4$ ). **(A)** After 18 hours, apoptosis of neutrophils was confirmed by 7-AAD and Annexin V. **(B-C)** Cells were cocultured for 1 h with CFSE-labeled apoptotic neutrophils for phagocytosis. Phagocytic activity (as % of CFSE<sup>+</sup> macrophages) was measured by flow cytometry ( $n = 4$ ). Bars show the mean  $\pm$  S.E.M. \* =  $p < 0.05$  by two-tailed paired t-test.


## **Clinical relevance of enhanced soluble CD62P, a marker of platelet activation, in RA patients**

Since previous study revealed an expansion of CD14<sup>+</sup>CD16<sup>+</sup> monocytes in peripheral blood of RA patients<sup>11</sup>, I next asked whether activated platelets are associated with increased CD16 expression on peripheral monocytes in RA patients. The patient characteristics of RA patients enrolled in this study are summarized in Table 1. A number of soluble factors, such as platelet factor 4 (PF4), soluble CD62P (sCD62P),  $\beta$ -thromboglobulin, and thromboxane, are known to be released from activated platelets<sup>40,41</sup>. In the present study, sCD62P was quantified in plasma and compared between RA patients and age-matched healthy controls (Fig. 19A). And patients in flare status have significantly higher plasma sCD62P levels than patients in remission, indicating increased activity of platelets (Fig. 19B). Consistent with previous reports<sup>42,43</sup>, RA patient plasma (mean  $\pm$  S.D.: 245.7  $\pm$  48.3 ng/ml,  $n = 32$ ) had a significantly higher amount of sCD62P than did that of HCs (126.4  $\pm$  48.3 ng/ml,  $n = 18$ ) ( $p < 0.0001$ ), suggesting that the presence of activated platelets is related to the expansion of CD14<sup>+</sup>CD16<sup>+</sup> monocytes in RA patients. Lastly, I sought to examine whether elevated levels of sCD62P in plasma are associated with clinical parameters and disease activity of RA patients. The amount of sCD62P in plasma had a significant positive correlation with the Disease Activity Score-28 (DAS28) for RA based on erythrocyte sedimentation rate (DAS28-

ESR) and C-reactive protein (DAS28-CRP), which represent enhanced inflammatory responses (Fig. 20,  $p = 0.0138$  and  $p = 0.0476$ , respectively). Together, these findings demonstrate that increased activity of platelets, which is represented by higher level of sCD62P in plasma, is positively correlated with RA clinical parameters. This suggests a possible mechanism for the accumulation of CD14<sup>+</sup>CD16<sup>+</sup> monocytes in RA patients.



**Figure 19. soluble CD62P, a marker of platelet activation, was increased in RA patients. (A)** sCD62P in plasma of, HCs ( $n = 18$ ) and RA patients ( $n = 32$ ) was quantitated by ELISA. Scatter plots show the mean  $\pm$  S.E.M. \*\*\*\* =  $p < 0.0001$  by two-tailed unpaired  $t$ -test. **(B)** sCD62P in plasma of HCs ( $n = 18$ ) and RA patients in remission ( $n = 11$ , DAS28  $< 2.6$ ) and flare ( $n = 6$ , DAS28  $> 5.1$ ) was quantitated by ELISA.  $P$  value was obtained using Pearson correlation analysis.



**Figure 20. Clinical relevance of enhanced soluble CD62P in RA patients.**

Correlation between sCD62P levels in the plasma of RA patients and RA clinical parameters ( $n = 32$ ). sCD62P levels were plotted against DAS28 ESR and DAS28 CRP.  $P$  value was obtained using Pearson correlation analysis.

## DISCUSSION

Monocytes are a versatile and dynamic cell population critical for the innate immune response during infections and autoimmune diseases<sup>2,4,10,44</sup>. Surface molecule expression patterns and transcriptomic profiles demonstrate that murine equivalents of classical CD14<sup>+</sup>CD16<sup>-</sup> and nonclassical CD14<sup>dim</sup>CD16<sup>+</sup> subsets in humans are the proinflammatory Ly6C<sup>hi</sup>CX<sub>3</sub>CR1<sup>mid</sup>CCR2<sup>+</sup> and patrolling Ly6C<sup>lo</sup>CX<sub>3</sub>CR1<sup>hi</sup>CCR2<sup>-</sup> populations, respectively. The CD14<sup>+</sup>CD16<sup>-</sup> subset mediates classical monocyte roles, such as initiation of the inflammatory response, recognition and phagocytosis of pathogens and production of proinflammatory cytokines, whereas nonclassical monocytes have anti-inflammatory properties and are involved in maintenance of vascular homeostasis<sup>4,44</sup>. In addition to the two monocyte subsets, a substantial number of intermediate CD14<sup>+</sup>CD16<sup>+</sup> monocytes exist in human peripheral blood. CD14<sup>+</sup>CD16<sup>+</sup> monocytes exhibit both phagocytic function and anti-inflammatory effects, as well as higher levels of intracellular IL-1 $\beta$  and TNF- $\alpha$  at steady state<sup>45,46</sup>. Research on the developmental trajectories of the three monocyte subsets in humans and in humanized mice suggests that intermediate monocytes exist in a transitory stage from classical to nonclassical monocytes at steady state and under experimental endotoxemia conditions<sup>10</sup>. A number of studies have shown that CD14<sup>+</sup>CD16<sup>+</sup> monocytes are expanded in peripheral blood and inflamed tissues during acute and

chronic inflammation such as is seen with inflammatory bowel disease (IBD) and rheumatoid arthritis (RA)<sup>11-13,34</sup>. Since the murine analogue to CD14<sup>+</sup>CD16<sup>+</sup> monocytes has not been clearly identified, little is known about mechanism underlying expression of CD16 and the immunological role of intermediate monocytes.


CD16 expression has been shown to be upregulated on monocytes in response to a number of different factors including platelets and several cytokines<sup>11,14,34</sup>. In agreement with an early report, these data show that activated platelets lead to a marked induction of CD16 expression on classical CD14<sup>+</sup> monocytes in a transcription-dependent manner (Fig. 3B)<sup>14</sup>. Several studies have demonstrated that induction of CD16 expression on monocytes is mediated by activated platelet-dependent COX-2 upregulation and consequent PGE2 synthesis in monocytes. Moreover, COX-2 synthesis is modulated by adhesion and signaling in response to cytokines such as platelet-derived TGF- $\beta$ 1 or monocyte-derived IL-1 $\beta$ <sup>47-49</sup>. Since MPAs are involved in secretion of soluble factors, including various cytokines<sup>15,50</sup>, I sought to determine which cytokines are capable of inducing CD16 on monocytes. Besides TGF- $\beta$ 1, a well-known inducer of CD16 on monocytes<sup>11,14</sup>, STAT3-activating cytokines IL-10 and IL-6 noticeably enhance CD16 expression, whereas IL-1 $\beta$  and TNF- $\alpha$ , major monocyte-derived pro-inflammatory cytokines, had an inhibitory effect on CD16 induction. The previous study showed that TGF- $\beta$ -induced CD16 expression

on monocytes was inhibited by IL-1 $\beta$  and TNF- $\alpha$ , but not IL-6<sup>11</sup>. Kinetics of cytokine production by MPA reveal that TGF- $\beta$  and IL-6 are involved in activated platelet-mediated induction of CD16 monocytes (Fig. 6 and 10). Although exogenous IL-10 is a potent inducer of CD16 on monocytes, as described previously and in the present study (Fig. 5)<sup>34</sup>, activated platelets have no ability to produce IL-10, nor do monocytes induce IL-10 production within 18 hr after co-culture. Moreover, an IL-10 neutralization assay corroborated these findings as IL-10 blockade had no effect on CD16 induction by MPAs (Fig. 10A). It has been demonstrated that CD14<sup>+</sup>CD16<sup>+</sup> intermediate monocytes are induced by IL-10 and positively correlate with disease activity in rheumatoid arthritis (RA)<sup>34</sup>. IL-10 is broadly produced by many types of immune cells<sup>51</sup>, and it has been suggested that CD16 expression on monocytes is maintained by IL-10 produced by human naïve CD4<sup>+</sup> T cells<sup>52</sup>. Induction of CD16 by IL-10 may occur in chronic inflammatory conditions including RA or during interactions with T cells. I showed that the majority of the TGF- $\beta$  was rapidly secreted from ADP-stimulated platelets in a transcription-independent manner and its production by monocytes in MPAs was minimal (Fig. 6B). Thus, hindrance of direct contact in the transwell system had no effect on CD16 induction on monocytes. However, IL-6 was produced solely by activated monocytes in MPAs in a transcription-dependent manner as seen in the Figure 6B. Immunoblotting of phosphorylation of the downstream mediators, SMAD3 and STAT3, revealed an obvious difference in the pattern and kinetics of

TGF- $\beta$  and IL-6 production in MPA. SMAD3 in monocytes is rapidly (before 30 min) phosphorylated only when cells are co-cultured with platelets, whereas phosphorylation of STAT3 was enhanced at later time points via IL-6 autocrine signaling. The critical role of TGF- $\beta$  and IL-6 for CD16 induction in MPA was clearly shown by inhibition with SB431542, SIS3, or 5, 15-DPP, which selectively inhibit TGF- $\beta$ RI, SMAD3, and STAT3, respectively (Fig. 21 and Fig. 12). It should be noted that IL-6 induced expression of COX2, which is important for CD16 induction on monocytes by activated platelets, is mediated by STAT3 in monocytic THP1 cells and prostatic tumor cells<sup>47,53,54</sup>.

Monocytes are highly sensitive to a variety of environmental stimuli including TLPAMP, DAMP, and even physical stimulation such as attachment. It has been reported that the adhesion of human monocytes to the cell culture dish leads to induction of synthesis of large amounts of IL-1 $\beta$  mRNA, a major proinflammatory cytokine produced by monocytes<sup>73,74</sup>. Human monocyte adhesion also causes cytoskeletal reorganization, which results in an increase of *IL-1 $\beta$*  mRNA stability and induction of *IL-1 $\beta$*  transcript redistribution<sup>75</sup>. Substantial evidence suggests that the cytoskeleton is involved in the spatial and temporal organization of critical components of the translational apparatus, and the control of translation. In fact, an unneglectable amount of IL-6 was produced at 3 h after culture without platelets and its level was increased during the time (Fig. 6B),

suggesting that monocytes produce IL-6 which may respond in an autocrine manner. Thus, in preliminary experiments, I carefully optimized the experimental protocol to minimize this unwanted effect. Monocytes were handled and kept in a polypropylene tube to minimize their attachment to the tube surface. Of course, I could not completely inhibit their attachment effect during the incubation. Presumably, the time-dependent secretion of IL-6, especially after 3 h of culture might result from their activation by attachment. However, it should be noted that monocytes cultured with ADP-activated platelets greatly upregulate phosphorylation of STAT3 compared with monocytes alone. In the culture system, TGF- $\beta$  is mainly produced by platelets stimulated by ADP (Fig. 7B). As seen in figure 7, activation of platelets occurs immediately upon ADP treatment, which leads to the secretion of TGF- $\beta$ 1 and further generation of active TGF- $\beta$ 1<sup>76</sup>. Since platelets express TGF- $\beta$  receptors<sup>77</sup>, active TGF- $\beta$ 1 induces phosphorylation of SMAD3 at very early time points after stimulation with ADP.



**Figure 21. Marked inhibition of activated platelet-induced CD16 by the TGF- $\beta$ RI inhibitor, SB431542.** Purified CD14<sup>+</sup>CD16<sup>-</sup> monocytes were pretreated with SB431542 (1  $\mu$ g/ml), followed by treatment with TGF- $\beta$  or ADP-activated platelets for 18 hr. (A) Representative contour plots of CD16 expression on monocytes under the indicated conditions. (B) Frequencies (%) of CD14<sup>+</sup>CD16<sup>+</sup> monocytes under the indicated conditions were analyzed using flow cytometry ( $n = 8$ ). Bars plots show the mean  $\pm$  S.E.M. \*\*\* =  $p < 0.005$  by two-tailed paired t-test.

Recent work has highlighted a cardinal role for platelets in inflammatory and immune responses by expressing and secreting many potent immunological mediators, such as FcγRIIA (CD32), CD154, TLRs, MHC class I molecules, cytokines, chemokines, and several granules including platelet factor 4 (PF4), glutamate, serotonin, and ADP<sup>15,18</sup>. Activated platelets shed microparticles that bud from their membranes<sup>30</sup> extending the reach of the activated platelet to sites distant from the cell itself<sup>55</sup>. Besides their well-known pathogenic role in atherosclerosis, platelets have been identified as active players in the pathogenesis of RA and SLE<sup>30,55,56</sup>. Anti-citrullinated protein antibodies (ACPA), which recognize a group of post-transcriptionally modified autoantigens in RA, contribute to platelet activation, and activated platelets release ADP themselves, further causing platelet activation<sup>57</sup>. Of note, serum soluble selectin levels including sCD62P are elevated in RA and systemic sclerosis. Thus, sCD62P has been suggested as a circulating biomarker in RA with thrombocytosis, indicating the presence of a continuous underlying inflammatory stimulus<sup>42,43</sup>. CD14<sup>+</sup>CD16<sup>+</sup>, but not CD14<sup>dim</sup>CD16<sup>+</sup>, monocytes were predominantly expanded in peripheral blood and synovial fluid of RA patients compared with healthy controls<sup>11</sup>. As seen in Figure 15, the concentration of sCD62P, a biomarker of activated platelets, was significantly increased in plasma of RA patients compared with that of healthy controls, implicating activated platelets in the induction of CD16 on

classical monocytes in RA. It should be noted that the expression of CD16 on CD14<sup>+</sup> monocytes is induced by synovial fluid in a dose-dependent manner and this upregulation is greatly inhibited by SB431542, a TGF- $\beta$ RI inhibitor<sup>11</sup>. In RA patients, the proportion of CD14<sup>+</sup>CD16<sup>+</sup> monocytes are positively correlated with clinical parameters, such as CRP and DAS28-ESR, and is significantly decreased after a 12 week-treatment with methotrexate (MTX), a gold standard, disease-modifying anti-rheumatic drug (DMARD)<sup>34</sup>. This is supported by these findings showing sCD62P concentration is significantly and positively correlated with RA clinical parameters including DAS28-ESR and DAS28-CRP (Fig. 16).

Human CD16 exists in two different isoforms, Fc $\gamma$ RIIIA (CD16A) and Fc $\gamma$ RIIIB (CD16B), encoded by separate genes<sup>58</sup>. Phillips et al showed that CD16 expressed on platelet-activated monocytes is structurally similar to the transmembrane-anchored CD16B polypeptide expressed on NK cells, but is associated with the Fc $\epsilon$ RI- $\gamma$  subunit in a manner identical to that of human basophils<sup>14</sup>. Therefore, it has been suggested that CD16 on monocytes contributes to antibody-dependent cellular cytotoxicity (ADCC) for targeting and killing virus-infected or transformed cells coated with specific antibodies<sup>59</sup>. ADCC by CD16<sup>+</sup> monocytes require cell-cell contact facilitated via  $\beta$ 2-integrins and mediated by TNF- $\alpha$ <sup>59</sup>. Besides ADCC, CD16 induced by activated platelets mediates antibody-dependent cellular phagocytosis (ADCP), showing that this phagocytic activity is

comparable to that of CD64/CD32-mediated phagocytosis in monocytes (Fig. 13A and B). These data illustrate that the phagocytic capacity largely depends on the platelet activity and the proportion of CD16<sup>+</sup>CD14<sup>+</sup> monocytes induced (Fig. 13B and C). Given that ADCC, ADCP, and complement-dependent cytotoxicity (CDC) are FcR-mediated effector functions which contribute to removal of antibody-opsonized target cells or molecules, induction of CD16 on monocytes is likely involved in regulation of immune responses and inflammatory reactions. Although not examined in the study, expanded CD14<sup>+</sup>CD16<sup>+</sup> monocytes in RA may result in an increased responsiveness to immune complex (IC)-stimulation<sup>60</sup>. Given that IgG-containing immune complexes (IC) including those containing rheumatoid factors (RFs) and cyclic citrullinated peptide (CCP) autoantibodies, are found abundantly in serum and synovial fluid of patients with RA, it could be one potential pathophysiological role of intermediate CD14<sup>+</sup>CD16<sup>+</sup> monocytes in RA.

A large number of circulating monocytes migrate into an inflamed tissue and generally differentiate into inflammatory macrophages during an inflammatory reaction. Recent single-cell transcriptome sequencing (scRNA-seq) analyses have shown that synovial monocytes/macrophages of RA patients and RA mouse model are heterogeneous, and these distinct subsets are closely linked to diverse homeostatic, regulatory, and inflammatory functions<sup>62-64</sup>. Leukocyte-rich RA synovia have a greater

abundance of *IL1B*<sup>+</sup> monocytes but a reduced *NUPRI*<sup>+</sup> monocytes, whereas *MerTK*<sup>+</sup> macrophages are associated with remission and maintenance of RA<sup>62,63</sup>. In present study, I found that incubation with activated platelets lead to skewing of monocytes toward differentiation into macrophages with an M2 propensity (Fig. 15 and 16). It is still debated whether platelet interactions with monocytes/macrophages elicit proinflammatory or anti-inflammatory responses upon various stimulations<sup>27,65-67</sup>. Of note, activated platelets alone induce anti-inflammatory responses of monocytes/macrophages via PGE<sub>2</sub> and cytokines<sup>67</sup>. In these study, ADP-activated monocytes appear to differentiate into CD16<sup>+</sup>CD163<sup>+</sup>MerTK<sup>+</sup> M2c macrophages that are polarized by IL-10, TGF- $\beta$ , or glucocorticoid and play crucial roles in the phagocytosis of apoptotic cells<sup>68</sup>. M-CSF is capable of inducing polarization of M2 macrophages that express CD16 and CD163 on monocytes during differentiation<sup>69</sup>. However, I found that monocytes pre-treated with ADP-platelets further increased the expression of CD16 and CD163 during differentiation in the presence of M-CSF compared with control. Furthermore, MerTK, a marker of M2c macrophages, was significantly upregulated in HMDMs pretreated with activated platelets. A recent study demonstrated that M2c-like cells are detectable among circulating CD14<sup>+</sup>CD16<sup>+</sup>, but not CD14<sup>dim</sup>CD16<sup>+</sup>, monocytes<sup>70</sup>. Considering that the protein expression of MerTK in macrophages is associated with, the ability to phagocytose apoptotic cells, a functional characteristic of M2c macrophages. I tested the ability of ADP-platelet polarized macrophages to

phagocytose apoptotic neutrophils compared to macrophages without ADP-activated platelets and found that ADP-platelet polarized macrophages have an enhanced phagocytic activity (Fig. 18). Phenotypic and functional results demonstrate that the monocyte-activated platelet co-cultures potentiate a polarization to M2 macrophages, and probably M2c-like macrophages.

In summary, I provide evidence that activated platelets are important for the induction of CD16 expression on classical CD14<sup>+</sup>CD16<sup>-</sup> monocytes through sequential involvement of platelet-derived TGF- $\beta$  and monocyte-derived IL-6. Induced CD16 on monocytes participates in IgG-mediated phagocytosis. In addition, monocytes pretreated with activated platelets preferentially differentiate into M2c-like macrophages in the presence of M-CSF. In RA patients, the plasma level of sCD62P, a marker of activated platelets, was significantly elevated, which may explain the accumulation of CD14<sup>+</sup>CD16<sup>+</sup> monocytes in RA patients. Furthermore, the sCD62P level in plasma is positively correlated with RA clinical parameters. These findings underscore a key role of activated platelets for regulating phenotypical and functional features of human monocytes and shed light on the immunological role of CD14<sup>+</sup>CD16<sup>+</sup> cells in a variety of inflammatory disorders.

## REFERENCES

1. Randolph, Gwendalyn J., et al. "Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo." *Immunity* 11.6 (1999): 753-761.
2. Geissmann, Frederic, Steffen Jung, and Dan R. Littman. "Blood monocytes consist of two principal subsets with distinct migratory properties." *Immunity* 19.1 (2003): 71-82.
3. Varol, Chen, et al. "Monocytes give rise to mucosal, but not splenic, conventional dendritic cells." *The Journal of experimental medicine* 204.1 (2007): 171-180.
4. Cros, Jérôme, et al. "Human CD14<sup>dim</sup> monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors." *Immunity* 33.3 (2010): 375-386.
5. Auffray, Cedric, Michael H. Sieweke, and Frederic Geissmann. "Blood monocytes: development, heterogeneity, and relationship with dendritic cells." *Annual review of immunology* 27 (2009): 669-692.
6. Shi, Chao, and Eric G. Pamer. "Monocyte recruitment during infection and inflammation." *Nature reviews immunology* 11.11 (2011): 762-774.
7. Geissmann, Frederic, et al. "Blood monocytes: distinct subsets, how they relate to dendritic cells, and their possible roles in the regulation of T-cell responses." *Immunology and cell biology* 86.5 (2008): 398-408.
8. Ingersoll, Molly A., et al. "Monocyte trafficking in acute and chronic inflammation." *Trends in immunology* 32.10 (2011): 470-477.
9. Wong, Kok Loon, et al. "The three human monocyte subsets: implications for health and disease." *Immunologic research* 53.1 (2012): 41-57.
10. Patel, Amit A., et al. "The fate and lifespan of human monocyte subsets in steady state and systemic inflammation." *Journal of Experimental Medicine* 214.7 (2017): 1913-1923.
11. Yoon, Bo Ruem, et al. "Functional phenotype of synovial monocytes modulating inflammatory T-cell responses in rheumatoid arthritis (RA)." *PloS one* 9.10 (2014): e109775.
12. Yoon, Bo Ruem, et al. "Functional phenotype of synovial monocytes modulating inflammatory T-cell responses in rheumatoid arthritis (RA)." *PloS one* 9.10 (2014): e109775.

13. Rossol, Manuela, et al. "The CD14<sup>bright</sup>CD16<sup>+</sup> monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population." *Arthritis & Rheumatism* 64.3 (2012): 671-677.
14. Phillips, Joseph H., Chiwen Chang, and Lewis L. Lanier. "Platelet-induced expression of FcγRIII (CD16) on human monocytes." *European journal of immunology* 21.4 (1991): 895-899.
15. Semple, John W., Joseph E. Italiano, and John Freedman. "Platelets and the immune continuum." *Nature Reviews Immunology* 11.4 (2011): 264-274.
16. von Hundelshausen, Philipp, and Christian Weber. "Platelets as immune cells: bridging inflammation and cardiovascular disease." *Circulation research* 100.1 (2007): 27-40.
17. Celi, Alessandro, et al. "P-selectin induces the expression of tissue factor on monocytes." *Proceedings of the National Academy of Sciences* 91.19 (1994): 8767-8771.
18. Morrell, Craig N., et al. "Emerging roles for platelets as immune and inflammatory cells." *Blood, The Journal of the American Society of Hematology* 123.18 (2014): 2759-2767.
19. Allen, Nicole, et al. "Circulating monocyte-platelet aggregates are a robust marker of platelet activity in cardiovascular disease." *Atherosclerosis* 282 (2019): 11-18.
20. Tay, Hui Min, et al. "Increased monocyte-platelet aggregates and monocyte-endothelial adhesion in healthy individuals with vitamin D deficiency." *The FASEB Journal* 34.8 (2020): 11133-11142.
21. Zahran, Asmaa M., et al. "Platelet activation and platelet–leukocyte aggregates in type I diabetes mellitus." *Clinical and Applied Thrombosis/Hemostasis* 24.9\_suppl (2018): 230S-239S.
22. Ashman, Neil, et al. "Increased platelet–monocyte aggregates and cardiovascular disease in end-stage renal failure patients." *Nephrology Dialysis Transplantation* 18.10 (2003): 2088-2096.
23. Knijff-Dutmer, E. A. J., et al. "Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis." *Arthritis & Rheumatism: Official Journal of the American College of Rheumatology* 46.6 (2002): 1498-1503.
24. Cloutier, Nathalie, et al. "Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration." *Proceedings of the National Academy of Sciences* 115.7 (2018): E1550-E1559.

25. Boilard, Eric, Patrick Blanco, and Peter A. Nigrovic. "Platelets: active players in the pathogenesis of arthritis and SLE." *Nature Reviews Rheumatology* 8.9 (2012): 534-542.
26. Burbano, Catalina, et al. "Potential involvement of platelet-derived microparticles and microparticles forming immune complexes during monocyte activation in patients with systemic lupus erythematosus." *Frontiers in immunology* 9 (2018): 322.
27. Carestia, Agostina, et al. "Platelets promote macrophage polarization toward pro-inflammatory phenotype and increase survival of septic mice." *Cell reports* 28.4 (2019): 896-908.
28. Zamora, Carlos, et al. "Binding of platelets to lymphocytes: a potential anti-inflammatory therapy in rheumatoid arthritis." *The Journal of Immunology* 198.8 (2017): 3099-3108.
29. Koupenova, Milka, et al. "Circulating platelets as mediators of immunity, inflammation, and thrombosis." *Circulation research* 122.2 (2018): 337-351.
30. Boilard, Eric, et al. "Platelets amplify inflammation in arthritis via collagen-dependent microparticle production." *Science* 327.5965 (2010): 580-583.
31. Kapellos, Theodore S., et al. "Human monocyte subsets and phenotypes in major chronic inflammatory diseases." *Frontiers in immunology* (2019): 2035.
32. Micklewright, J. J., J. A. Layhadi, and S. J. Fountain. "P2Y12 receptor modulation of ADP-evoked intracellular Ca<sup>2+</sup> signalling in THP-1 human monocytic cells." *British journal of pharmacology* 175.12 (2018): 2483-2491.
33. Gudbrandsdottir, Sif, Hans C. Hasselbalch, and Claus H. Nielsen. "Activated platelets enhance IL-10 secretion and reduce TNF- $\alpha$  secretion by monocytes." *The Journal of Immunology* 191.8 (2013): 4059-4067.
34. Tsukamoto, Masako, et al. "CD14 bright CD16<sup>+</sup> intermediate monocytes are induced by interleukin-10 and positively correlate with disease activity in rheumatoid arthritis." *Arthritis research & therapy* 19.1 (2017): 1-10.
35. Bournazos, Stylianos, et al. "Signaling by antibodies: recent progress." *Annual review of immunology* 35 (2017): 285-311.
36. Junker, Fabian, John Gordon, and Omar Qureshi. "Fc gamma receptors and their role in antigen uptake, presentation, and T cell activation." *Frontiers in Immunology* (2020): 1393.

37. Murray, Peter J. "Macrophage polarization." *Annual review of physiology* 79 (2017): 541-566.
38. Yoon, Bo Ruen, et al. "Role of SLC7A5 in metabolic reprogramming of human monocyte/macrophage immune responses." *Frontiers in immunology* 9 (2018): 53.
39. Wang, Le-xun, et al. "M2b macrophage polarization and its roles in diseases." *Journal of leukocyte biology* 106.2 (2019): 345-358.
40. Gurney, David, Gregory YH Lip, and Andrew D. Blann. "A reliable plasma marker of platelet activation: does it exist?." *American journal of hematology* 70.2 (2002): 139-144.
41. Kannan, Meganathan, Firdos Ahmad, and Renu Saxena. "Platelet activation markers in evaluation of thrombotic risk factors in various clinical settings." *Blood Reviews* 37 (2019): 100583.
42. Ateş, A., et al. "Serum-Soluble Selectin Levels in Patients with Rheumatoid Arthritis and Systemic Sclerosis." *Scandinavian journal of immunology* 59.3 (2004): 315-320.
43. Ertenli, I., et al. "P-selectin as a circulating molecular marker in rheumatoid arthritis with thrombocytosis." *The Journal of rheumatology* 25.6 (1998): 1054-1058
44. Ingersoll, Molly A., et al. "Comparison of gene expression profiles between human and mouse monocyte subsets." *Blood, The Journal of the American Society of Hematology* 115.3 (2010): e10-e19.
45. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets.
46. Kratofil, Rachel M., Paul Kubes, and Justin F. Deniset. "Monocyte conversion during inflammation and injury." *Arteriosclerosis, thrombosis, and vascular biology* 37.1 (2017): 35-42.
47. Passacuale, Gabriella, et al. "Monocyte-platelet interaction induces a pro-inflammatory phenotype in circulating monocytes." *PloS one* 6.10 (2011): e25595.
48. Eligini, Sonia, et al. "Paracrine up-regulation of monocyte cyclooxygenase-2 by platelets: Role of transforming growth factor- $\beta$ 1." *Cardiovascular research* 74.2 (2007): 270-278.
49. Dixon, Dan A., et al. "Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling." *The Journal of clinical investigation* 116.10 (2006): 2727-2738.

50. Lam, Fong W., K. Vinod Vijayan, and Rolando E. Rumbaut. "Platelets and their interactions with other immune cells." *Comprehensive Physiology* 5.3 (2015): 1265.
51. Saraiva, Margarida, and Anne O'garra. "The regulation of IL-10 production by immune cells." *Nature reviews immunology* 10.3 (2010): 170-181.
52. Liu, Yun, et al. "Interleukin-21 maintains the expression of CD16 on monocytes via the production of IL-10 by human naive CD4+ T cells." *Cellular immunology* 267.2 (2011): 102-108.
53. Basu, Anandita, et al. "STAT3 and NF- $\kappa$ B are common targets for kaempferol-mediated attenuation of COX-2 expression in IL-6-induced macrophages and carrageenan-induced mouse paw edema." *Biochemistry and biophysics reports* 12 (2017): 54-61.
54. Liu, Xin-Hua, et al. "Prostaglandin E2 stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway." *Biochemical and biophysical research communications* 290.1 (2002): 249-255.
55. Andersson, Gunilla, Tony Axéll, and Åke Larsson. "Impact of consumption factors on soft tissue changes in Swedish moist snuff users: a histologic study." *Journal of oral pathology & medicine* 19.10 (1990): 453-458.
56. Davì, Giovanni, and Carlo Patrono. "Platelet activation and atherothrombosis." *New England Journal of Medicine* 357.24 (2007): 2482-2494.
57. Habets, Kim LL, et al. "Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis." *Arthritis research & therapy* 17.1 (2015): 1-13.
58. Zhang, Yihong, et al. "Crystal structure of the extracellular domain of a human Fc $\gamma$ RIII." *Immunity* 13.3 (2000): 387-395.
59. Yeap, Wei Hseun, et al. "CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes." *Scientific reports* 6.1 (2016): 1-22.
60. Cooper, Dawn L., et al. "Fc $\gamma$ RIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate therapy." *PloS one* 7.1 (2012): e28918.
61. Italiani, Paola, and Diana Boraschi. "From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation." *Frontiers in immunology* (2014): 514.

62. Alivernini, Stefano, et al. "Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis." *Nature medicine* 26.8 (2020): 1295-1306.
63. Zhang, Fan, et al. "Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry." *Nature immunology* 20.7 (2019): 928-942.
64. Culemann, Stephan, et al. "Locally renewing resident synovial macrophages provide a protective barrier for the joint." *Nature* 572.7771 (2019): 670-675.
65. Olumuyiwa-Akeredolu, Oore-ofe, et al. "Platelets: emerging facilitators of cellular crosstalk in rheumatoid arthritis." *Nature Reviews Rheumatology* 15.4 (2019): 237-248.
66. Andia, Isabel. "The ins and outs of platelets in RA." *Nature Reviews Rheumatology* 13.5 (2017): 262-264.
67. Linke, Bona, et al. "Activated platelets induce an anti-inflammatory response of monocytes/macrophages through cross-regulation of PGE2 and cytokines." *Mediators of Inflammation* 2017 (2017).
68. Röszer, Tamás. "Understanding the mysterious M2 macrophage through activation markers and effector mechanisms." *Mediators of inflammation* 2015 (2015).
69. Sierra-Filardi, Elena, et al. "Heme Oxygenase-1 expression in M-CSF-polarized M2 macrophages contributes to LPS-induced IL-10 release." *Immunobiology* 215.9-10 (2010): 788-795.
70. Zizzo, Gaetano, et al. "Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MerTK induction." *The Journal of Immunology* 189.7 (2012): 3508-3520.
71. Porta, Chiara, et al. "Molecular and epigenetic basis of macrophage polarized activation." *Seminars in immunology*. Vol. 27. No. 4. Academic Press, 2015.
72. Chistiakov, Dimitry A., et al. "RETRACTED: Macrophage phenotypic plasticity in atherosclerosis: the associated features and the peculiarities of the expression of inflammatory genes." *International journal of cardiology* 184 (2015): 436-445.
73. Sirenko, Oksana, et al. "IL-1 $\beta$  transcript stability in monocytes is linked to cytoskeletal reorganization and the availability of mRNA degradation factors." *Immunology and cell biology* 80.4 (2002): 328-339.
74. Mondal, Krishna, et al. "Differential role of tyrosine phosphorylation in adhesion-induced transcription, mRNA stability, and cytoskeletal

- organization in human monocytes." *Journal of leukocyte biology* 67.2 (2000): 216-225.
75. Kim, Seyun, and Pierre A. Coulombe. "Emerging role for the cytoskeleton as an organizer and regulator of translation." *Nature reviews Molecular cell biology* 11.1 (2010): 75-81.
  76. Blakytny, Robert, et al. "Latent TGF- $\beta$ 1 activation by platelets." *Journal of cellular physiology* 199.1 (2004): 67-76.
  77. Lev, P. R., et al. "Platelets possess functional TGF- $\beta$  receptors and Smad2 protein." *Platelets* 18.1 (2007): 35-42.
  78. Jaguin, Marie, et al. "Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin." *Cellular immunology* 281.1 (2013): 51-61.

## 국문 초록

단핵구는 선천 면역 방어체계의 중요한 세포이다. 인간 단핵구는 다양한 종류가 존재하고, 특히 CD14 및 CD16 발현에 따라 크게 3가지로 분류된다. CD14<sup>+</sup>CD16<sup>+</sup> 단핵구 증가가 류마티스 관절염을 포함한 만성 염증성 질환에서 꾸준히 보고되었으나, 전형적인 단핵구인 CD14<sup>+</sup>CD16<sup>-</sup> 단핵구에서 CD16 유도기전과 그 역할에 대해서는 알려진 바가 많지 않다. 본 학위논문에서는, 사이토카인과 같은 용해성 인자를 통해서 CD14<sup>+</sup>CD16<sup>-</sup>에서 CD16 유도하는데 중요한 역할을 하는 활성화 혈소판에 대하여 연구하였다. 사이토카인에 대한 중화항체와 관련 신호전달계 억제제를 활용한 분석을 통하여 혈소판 유래 TGF- $\beta$  및 단핵구 유래 IL-6가 순차적으로 작동하여 CD14<sup>+</sup>CD16<sup>-</sup> 단핵구에서 CD16 유도에 기여한다는 것을 밝혀냈다. 활성화된 혈소판에 의해 단핵구에 발현이 증가된 CD16 분자는 항체-의존 세포성 식세포증 (antibody-dependent cellular phagocytosis (ADCP)에 관여하며, CD16의 발현정도는 식세포 능력과 양의 상관관계를 나타냄을 확인하였다. 활성화된 혈소판으로 처리된 CD14<sup>+</sup>CD16<sup>-</sup> 단핵구는 M2의 특징을 나타내는 대식세포로 주로 분화되었고, M2c 대식세포에서 특징적인 CD163과 MerTK를 발현하였다. 마지막으로, 혈소판의 활성화정도를 나타내는 마커인 sCD62P

의 양은 류마티스 관절염 환자의 혈장에서 유의적으로 증가하였고 이는 류마티스 관절염의 임상증상과 유의적인 양의 상관관계를 보였다. 이러한 결과는 인간 단핵구의 표현형 및 기능적 특징을 조절하는데 있어 활성화된 혈소판이 중요한 역할을 하고 있음을 시사하며 이러한 지식은 만성 염증성 질환에서 CD14<sup>+</sup>CD16<sup>+</sup> 세포의 면역학적 역할에 대한 이해를 증가시키는데 도움을 줄 것으로 사료된다.

주요어 : 혈소판, CD14<sup>+</sup>CD16<sup>+</sup> 단핵구, TGF- $\beta$ , IL-6, 식세포 작용, M2 대식세포, 류마티스 관절염, 용해성 CD62p, MerTK

학번 : 2018-25031